Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research ...

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities ...

Scholar Rock’s latest earnings call struck a cautiously optimistic tone, with management emphasizing regulatory traction, a deepening neuromuscular pipeline, and a visibly maturing commercial ...

Bureaucracy's Rot Runs Amok at FDA ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that ...

This Sleep Awareness Week, RENPHO, the global leader in smart wellness innovation, is spotlighting one of the most overlooked performance tools in an elite athlete's arsenal: sleep. Rest isn't just ...

Clinical & Scientific Conference, researchers and clinicians are talking about the central role of patients, families, and caregivers in driving change for people living with neuromuscular diseases.

Keros Therapeutics KROS is focused on developing and commercializing novel therapeutics to treat a wide range of patients ...

Permanent; Fitzroy location; Challenging and rewarding work environment; About the Role An opportunity is available for a Grade 3 Physiotherapist to join the ...